The approach allows more rapid detection of resistant strains as well as detection of certain populations for which good clinical assays don't currently exist.
The technology is being used to analyze pathogen samples in a clinical study examining methods to combat recurrent drug-resistant Staph infections.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
If approved, the multiplex Staph panel will grow the firm's menu of assays on its molecular platform to three.
Genome sequencing is a new tool in the fight against drug-resistant bacteria, writes Lara Marks at The Conversation.
GeneWeave's rule-in antibiotic susceptibility testing works where PCR doesn't and offers Roche the possibility of reshaping the microbiology laboratory.
In Genome Biology this week: MRSA genetic diversity, genome features linked to bee sociality, and more.
The study evaluated three commonly used tests, and found that slight differences in specificity could lead to unnecessary patient isolation.
The company plans to offer 3.75 million shares of its stock at $8 to $10 per share, and anticipates listing on the Nasdaq under ticker symbol "OPGN."
The test runs on Roche's cobas 4800 system and is cleared for the early, simultaneous detection of MRSA and SA directly from nasal specimens.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.